Drug-Induced Liver Injury After COVID-19 Vaccine

Rupinder Mann1, Sommer Sekhon2, Sandeep Sekhon3

  • 1Internal Medicine, Saint Agnes Medical Center, Fresno, USA.

Cureus
|August 25, 2021
PubMed

Insights

COVID-19 vaccines are safe, but rare cases of liver injury have been reported. This case study details a patient experiencing liver injury following COVID-19 vaccination.

Area of Science:

  • Hepatology
  • Vaccinology
  • Infectious Diseases

Background:

  • The COVID-19 pandemic, caused by SARS-CoV-2, has led to widespread morbidity and mortality.
  • Numerous vaccines have been developed and approved, demonstrating high safety and efficacy.
  • Drug-induced liver injury (DILI) is a known concern, though rare with vaccines.

Observation:

  • A case of liver injury following COVID-19 vaccination is presented.
  • The patient developed symptoms indicative of hepatic distress post-vaccination.
  • Diagnostic workup confirmed liver injury potentially linked to the vaccine.

Findings:

  • The presented case highlights a rare instance of hepatotoxicity after COVID-19 vaccination.
  • While vaccines have excellent safety profiles, monitoring for adverse events remains crucial.
  • This case contributes to the understanding of potential vaccine-related side effects.

Implications:

  • Further investigation into rare vaccine-associated liver injury is warranted.
  • Clinicians should be aware of potential hepatotoxicity in patients presenting with liver issues post-vaccination.
  • Continued pharmacovigilance is essential for ensuring vaccine safety and public trust.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
37
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
36
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
33
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
34
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
33
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.4K